european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
  • Science News
  • Resources

Vaccines

innovative biologics 2026

Innovative Biologics Expected Approvals in 2026

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines

Monoclonal Antibody Prophylaxis for Infectious Diseases

Monoclonal Antibody Prophylaxis for Infectious Diseases – Passive Immunization and Prevention

Monoclonal antibody, Vaccines

Mammalian Cell Lines as a Platform for Protein Vaccine Production

Cell culture, Drug substance, Manufacturing, Proteins, Vaccines

Innovative biologics that are expected to be approved in 2025

Innovative Biologics – Expected Drug Approvals in 2025

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines

Novavax and Mabion Partnership on COVID-19 Vaccine

A synergy of excellence: Novavax-Mabion partnership on vaccine during unprecedented times amid the COVID-19 pandemic

Mabion, Vaccines

FDA approved biologics in 2023

Top 10 biologics approved in 2023

Biologics, EMA, FDA, Monoclonal antibody, Vaccines

latest trends in the prevention and treatment of cervical cancer

Latest trends in the prevention and treatment of cervical cancer

Cancer, Vaccines

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Powered by

    Veneo